Radiation-induced Esophagitis - Pipeline Insight, 2024

Radiation-induced Esophagitis - Pipeline Insight, 2024

DelveInsight’s, “Radiation-induced Esophagitis – Pipeline Insight, 2024,” report provides comprehensive insights about companies and pipeline drugs in Radiation-induced Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Radiation-induced Esophagitis Understanding

Radiation-induced Esophagitis: Overview

Radiation-induced esophagitis is a consequence of radiotherapy toxicity over the esophagus resulting in both acute or chronic complications. It is an aseptic inflammation of esophageal mucosa. The radiation mainly causes the esophageal mucosal injury. The main effector cells are monocytes and macrophages, which are over-activated in response to radiation stimulation and release a large number of inflammatory mediators, such as IL-6, IL-10 and TNF-α, leading to pathological damage. The target cells of acute radiation-induced esophageal injury are mucosal basal cells. Radiation also induces oxidative stress through the formation of hydroxyl radicals by the decomposition of water molecules in esophageal tissue to cause the damage to normal esophageal tissues.

Symptoms

The pathological manifestations of radiation-induced esophagitis are congestion, edema, erosions, inflammatory exudative changes or even ulcers of the esophagus. The clinical manifestations were dysphagia, pain, burning sensation and aggravation after eating.

Diagnosis

Radiation induced esophagitis can be generally diagnosed clinically and seldom is specific workup needed. Endoscopy is helpful not only in diagnosing and treating late esophageal strictures but also in differentiating radiation injury from infectious esophagitis. Histologic findings typical of late RT (radiation therapy) esophagitis include chronic-appearing inflammation, fibrosis, and atypia in biopsies taken from the radiated field, with tissue sampling essential to rule out recurrent malignancy

Treatment

Treatment of Radiation-induced Esophagitis involves the use of medicines to relieve esophageal smooth muscle spasm, inhibit gastric acid secretion, induce detumescence by using high doses of anti-inflammatory medicines. A commercially available drug called Ethyol (amifostine), which is a radiation protector, can be administered via injection 30 minutes prior to each radiation treatment. This can reduce radiation esophagitis and has been studied most extensively in the setting of lung cancer. The goals of treating esophagitis are to keep the person comfortable and to maintain nutrition, body weight, and fluid intake. High-calorie liquids, puddings, and custards are good choices. Softening one’s diet, avoiding extremely hot or cold foods, and refraining from alcohol and spicy food is the first step in alleviating the discomfort of esophagitis.

Radiation-induced Esophagitis Emerging Drugs Chapters

This segment of the Radiation-induced Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Radiation-induced Esophagitis Emerging Drugs

• GC4419: Galera Therapeutics

GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. It has been demonstrated proof-of-concept with GC4419 for this use in a randomized, double-blinded, placebo-controlled 223-patient Phase 2b trial. In the trial, GC4419 met the primary endpoint by demonstrating a 92% reduction in median duration of SOM in the 90 mg treatment arm as compared to placebo, which was statistically significant and consistent with the results of our Phase 1b/2a SOM trial. Key secondary endpoints evaluating the incidence and severity of SOM also demonstrated substantial dose-dependent reductions of 34% and 47%, respectively, in the 90 mg treatment arm, and GC4419 was well tolerated in this trial.

Further product details are provided in the report……..

Radiation-induced Esophagitis: Therapeutic Assessment

This segment of the report provides insights about the different Radiation-induced Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Radiation-induced Esophagitis

There are approx. 1+ key companies which are developing the therapies for Radiation-induced Esophagitis. The companies which have their Radiation-induced Esophagitis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Galera Therapeutics and others.

Phases

DelveInsight’s report covers around 1+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Radiation-induced Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Radiation-induced Esophagitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Radiation-induced Esophagitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Radiation-induced Esophagitis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Radiation-induced Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve Radiation-induced Esophagitis.

Radiation-induced Esophagitis Report Insights

• Radiation-induced Esophagitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Radiation-induced Esophagitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Radiation-induced Esophagitis drugs?
• How many Radiation-induced Esophagitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Radiation-induced Esophagitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Radiation-induced Esophagitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Radiation-induced Esophagitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Galera Therapeutics

Key Products

• GC4419